Login to Your Account

NewCo News

GeNeuro Targeting Retrovirus Via MAbs in MS, Schizophrenia

By Marie Powers
Staff Writer

Monday, November 26, 2012

Spun out in 2006 from French diagnostics firm BioMérieux SA with the help of Swiss bioincubator Eclosion, GeNeuro SA has slowly but steadily progressed its monoclonal antibody (mAb) technology – initially to prevent the inflammatory and autoimmune cascades induced by the multiple sclerosis-associated retrovirus (MSRV).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription